Solutions
Same evidence. Different question.
A CRO defending a bid, an investor sizing a risk and a sponsor choosing an indication are all asking the feasibility question — from different sides. Each page below is that reader's version of it.
One assessment, six audiences
Solutions
Pick the one that looks like your week.
Every page below runs the same six pillars and the same seven expert roles. What changes is which parts are load-bearing, and what lands on your desk at the end.
Service provider
For CROs
Cited, auditable feasibility you can white-label into a bid — and defend line by line when the sponsor pushes back.
Capital
For investors
An independent, fully cited read on a clinical-stage asset — built from public data, so no data room has to open first.
Sponsor
For emerging biotech
One asset, one shot, a finite runway — pressure-test the trial on public evidence before the protocol locks.
Sponsor
For medical affairs & R&D leaders
The evidence base behind every claim, comparator and design choice — assembled, cited, and re-checkable when it changes.
Sponsor
For academic & non-profit sponsors
Test whether the trial fits the funding envelope before the application goes in — with citations a review panel can check.
Deal-making
For biotech business development
An independent read on the asset across the table — valuation, runway and execution risk, built before the data room opens.
See a verdict you can actually check.
Send us a protocol — or just a molecule and an indication. We'll return a fully cited feasibility assessment you can trace, line by line, back to public data — yours to defend in a bid, take to your board or investment committee, or hand to a regulator.